Global Heparin Market 2024-2028

Technavio has been monitoring the heparin market and is poised to grow by $3.34bn from 2023-2027, accelerating at a CAGR of 7.22% during the forecast period. Our report on the heparin market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

Market Scope
Base Year	2023
End Year	2028
Series Year	2024-2028
Growth Momentum	Accelerate
YOY 2024	6.75%
CAGR	7.22%
Incremental Value	$3.34bn

The report offers an up-to-date analysis regarding the current global market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the increasing prevalence of coagulation disorders, the increasing prevalence of chronic conditions, and the reintroduction of alternative sources to produce heparin.

Technavio's heparin market is segmented as below:

By Product

Low-molecular-weight heparin
Others

By Route of Administration

Subcutaneous injection
Intravenous/infusion

By Geographical Landscape

Europe
North America
Asia
Rest of World (ROW)

This study identifies the increasing R&D activities and new therapeutic applications of heparin as one of the prime reasons driving the heparin market growth during the next few years. Also, the advent of biosimilar low-molecular-weight heparin and the development of drugs to remove heparin after surgery will lead to sizable demand in the market.

Heparin market sizing
Heparin market forecast
Heparin market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading heparin market vendors that include Aspen Pharmacare Holdings, B. Braun SE, Baxter International Inc., Dr Reddys Laboratories Ltd., Eisai Co. Ltd., Fresenius SE and Co. KGaA, Hebei Changshan Biochemical, Hikma Pharmaceuticals Plc, Laboratorios Farmaceuticos Rovi, LEO Pharma AS, Nanjing Kingfriend Biochemical, Nichi Iko Pharmaceutical Co. Ltd., Novartis AG, Opocrin SpA, Pfizer Inc., Sanofi SA, Shanghai Fosun Pharmaceutical Group Co. Ltd., Shenzhen Techdow Pharmaceutical, Teva Pharmaceutical Industries Ltd., and Viatris Inc. Also, the heparin market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Product Code: IRTNTR40831

1 Executive Summary

1.1 Market overview
Exhibit 01: Executive Summary - Chart on Market Overview
Exhibit 02: Executive Summary - Data Table on Market Overview
Exhibit 03: Executive Summary - Chart on Global Market Characteristics
Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
Exhibit 05: Executive Summary - Chart on Market Segmentation by Product
Exhibit 06: Executive Summary - Chart on Market Segmentation by Route of Administration
Exhibit 07: Executive Summary - Chart on Incremental Growth
Exhibit 08: Executive Summary - Data Table on Incremental Growth
Exhibit 09: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape

2.1 Market ecosystem
Exhibit 10: Parent market
Exhibit 11: Market Characteristics

3 Market Sizing

3.1 Market definition
Exhibit 12: Offerings of vendors included in the market definition
3.2 Market segment analysis
Exhibit 13: Market segments
3.3 Market size 2023
3.4 Market outlook: Forecast for 2023-2028
Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ billion)
Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ billion)
Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)

4 Historic Market Size

4.1 Global heparin market 2018 - 2022
Exhibit 18: Historic Market Size - Data Table on global heparin market 2018 - 2022 ($ billion)
4.2 Product Segment Analysis 2018 - 2022
Exhibit 19: Historic Market Size - Product Segment 2018 - 2022 ($ billion)
4.3 Route Of Administration Segment Analysis 2018 - 2022
Exhibit 20: Historic Market Size - Route Of Administration Segment 2018 - 2022 ($ billion)
4.4 Geography Segment Analysis 2018 - 2022
Exhibit 21: Historic Market Size - Geography Segment 2018 - 2022 ($ billion)
4.5 Country Segment Analysis 2018 - 2022
Exhibit 22: Historic Market Size - Country Segment 2018 - 2022 ($ billion)

5 Five Forces Analysis

5.1 Five forces summary
Exhibit 23: Five forces analysis - Comparison between 2023 and 2028
5.2 Bargaining power of buyers
Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
5.3 Bargaining power of suppliers
Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
5.4 Threat of new entrants
Exhibit 26: Threat of new entrants - Impact of key factors in 2023 and 2028
5.5 Threat of substitutes
Exhibit 27: Threat of substitutes - Impact of key factors in 2023 and 2028
5.6 Threat of rivalry
Exhibit 28: Threat of rivalry - Impact of key factors in 2023 and 2028
5.7 Market condition
Exhibit 29: Chart on Market condition - Five forces 2023 and 2028

6 Market Segmentation by Product

6.1 Market segments
Exhibit 30: Chart on Product - Market share 2023-2028 (%)
Exhibit 31: Data Table on Product - Market share 2023-2028 (%)
6.2 Comparison by Product
Exhibit 32: Chart on Comparison by Product
Exhibit 33: Data Table on Comparison by Product
6.3 Low-molecular-weight heparin - Market size and forecast 2023-2028
Exhibit 34: Chart on Low-molecular-weight heparin - Market size and forecast 2023-2028 ($ billion)
Exhibit 35: Data Table on Low-molecular-weight heparin - Market size and forecast 2023-2028 ($ billion)
Exhibit 36: Chart on Low-molecular-weight heparin - Year-over-year growth 2023-2028 (%)
Exhibit 37: Data Table on Low-molecular-weight heparin - Year-over-year growth 2023-2028 (%)
6.4 Others - Market size and forecast 2023-2028
Exhibit 38: Chart on Others - Market size and forecast 2023-2028 ($ billion)
Exhibit 39: Data Table on Others - Market size and forecast 2023-2028 ($ billion)
Exhibit 40: Chart on Others - Year-over-year growth 2023-2028 (%)
Exhibit 41: Data Table on Others - Year-over-year growth 2023-2028 (%)
6.5 Market opportunity by Product
Exhibit 42: Market opportunity by Product ($ billion)
Exhibit 43: Data Table on Market opportunity by Product ($ billion)

7 Market Segmentation by Route of Administration

7.1 Market segments
Exhibit 44: Chart on Route of Administration - Market share 2023-2028 (%)
Exhibit 45: Data Table on Route of Administration - Market share 2023-2028 (%)
7.2 Comparison by Route of Administration
Exhibit 46: Chart on Comparison by Route of Administration
Exhibit 47: Data Table on Comparison by Route of Administration
7.3 Subcutaneous injection - Market size and forecast 2023-2028
Exhibit 48: Chart on Subcutaneous injection - Market size and forecast 2023-2028 ($ billion)
Exhibit 49: Data Table on Subcutaneous injection - Market size and forecast 2023-2028 ($ billion)
Exhibit 50: Chart on Subcutaneous injection - Year-over-year growth 2023-2028 (%)
Exhibit 51: Data Table on Subcutaneous injection - Year-over-year growth 2023-2028 (%)
7.4 Intravenous infusion - Market size and forecast 2023-2028
Exhibit 52: Chart on Intravenous infusion - Market size and forecast 2023-2028 ($ billion)
Exhibit 53: Data Table on Intravenous infusion - Market size and forecast 2023-2028 ($ billion)
Exhibit 54: Chart on Intravenous infusion - Year-over-year growth 2023-2028 (%)
Exhibit 55: Data Table on Intravenous infusion - Year-over-year growth 2023-2028 (%)
7.5 Market opportunity by Route of Administration
Exhibit 56: Market opportunity by Route of Administration ($ billion)
Exhibit 57: Data Table on Market opportunity by Route of Administration ($ billion)

8 Customer Landscape

8.1 Customer landscape overview
Exhibit 58: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

9.1 Geographic segmentation
Exhibit 59: Chart on Market share By Geographical Landscape 2023-2028 (%)
Exhibit 60: Data Table on Market share By Geographical Landscape 2023-2028 (%)
9.2 Geographic comparison
Exhibit 61: Chart on Geographic comparison
Exhibit 62: Data Table on Geographic comparison
9.3 Europe - Market size and forecast 2023-2028
Exhibit 63: Chart on Europe - Market size and forecast 2023-2028 ($ billion)
Exhibit 64: Data Table on Europe - Market size and forecast 2023-2028 ($ billion)
Exhibit 65: Chart on Europe - Year-over-year growth 2023-2028 (%)
Exhibit 66: Data Table on Europe - Year-over-year growth 2023-2028 (%)
9.4 North America - Market size and forecast 2023-2028
Exhibit 67: Chart on North America - Market size and forecast 2023-2028 ($ billion)
Exhibit 68: Data Table on North America - Market size and forecast 2023-2028 ($ billion)
Exhibit 69: Chart on North America - Year-over-year growth 2023-2028 (%)
Exhibit 70: Data Table on North America - Year-over-year growth 2023-2028 (%)
9.5 Asia - Market size and forecast 2023-2028
Exhibit 71: Chart on Asia - Market size and forecast 2023-2028 ($ billion)
Exhibit 72: Data Table on Asia - Market size and forecast 2023-2028 ($ billion)
Exhibit 73: Chart on Asia - Year-over-year growth 2023-2028 (%)
Exhibit 74: Data Table on Asia - Year-over-year growth 2023-2028 (%)
9.6 Rest of World (ROW) - Market size and forecast 2023-2028
Exhibit 75: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
Exhibit 76: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
Exhibit 77: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
Exhibit 78: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
9.7 US - Market size and forecast 2023-2028
Exhibit 79: Chart on US - Market size and forecast 2023-2028 ($ billion)
Exhibit 80: Data Table on US - Market size and forecast 2023-2028 ($ billion)
Exhibit 81: Chart on US - Year-over-year growth 2023-2028 (%)
Exhibit 82: Data Table on US - Year-over-year growth 2023-2028 (%)
9.8 UK - Market size and forecast 2023-2028
Exhibit 83: Chart on UK - Market size and forecast 2023-2028 ($ billion)
Exhibit 84: Data Table on UK - Market size and forecast 2023-2028 ($ billion)
Exhibit 85: Chart on UK - Year-over-year growth 2023-2028 (%)
Exhibit 86: Data Table on UK - Year-over-year growth 2023-2028 (%)
9.9 Germany - Market size and forecast 2023-2028
Exhibit 87: Chart on Germany - Market size and forecast 2023-2028 ($ billion)
Exhibit 88: Data Table on Germany - Market size and forecast 2023-2028 ($ billion)
Exhibit 89: Chart on Germany - Year-over-year growth 2023-2028 (%)
Exhibit 90: Data Table on Germany - Year-over-year growth 2023-2028 (%)
9.10 China - Market size and forecast 2023-2028
Exhibit 91: Chart on China - Market size and forecast 2023-2028 ($ billion)
Exhibit 92: Data Table on China - Market size and forecast 2023-2028 ($ billion)
Exhibit 93: Chart on China - Year-over-year growth 2023-2028 (%)
Exhibit 94: Data Table on China - Year-over-year growth 2023-2028 (%)
9.11 France - Market size and forecast 2023-2028
Exhibit 95: Chart on France - Market size and forecast 2023-2028 ($ billion)
Exhibit 96: Data Table on France - Market size and forecast 2023-2028 ($ billion)
Exhibit 97: Chart on France - Year-over-year growth 2023-2028 (%)
Exhibit 98: Data Table on France - Year-over-year growth 2023-2028 (%)
9.12 Market opportunity By Geographical Landscape
Exhibit 99: Market opportunity By Geographical Landscape ($ billion)
Exhibit 100: Data Tables on Market opportunity By Geographical Landscape ($ billion)

10 Drivers, Challenges, and Trends

10.1 Market drivers
10.2 Market challenges
10.3 Impact of drivers and challenges
Exhibit 101: Impact of drivers and challenges in 2023 and 2028
10.4 Market trends

11 Vendor Landscape

11.1 Overview
11.2 Vendor landscape
Exhibit 102: Overview on Criticality of inputs and Factors of differentiation
11.3 Landscape disruption
Exhibit 103: Overview on factors of disruption
11.4 Industry risks
Exhibit 104: Impact of key risks on business

12 Vendor Analysis

12.1 Vendors covered
Exhibit 105: Vendors covered
12.2 Market positioning of vendors
Exhibit 106: Matrix on vendor position and classification
12.3 Aspen Pharmacare Holdings Ltd
Exhibit 107: Aspen Pharmacare Holdings Ltd - Overview
Exhibit 108: Aspen Pharmacare Holdings Ltd - Business segments
Exhibit 109: Aspen Pharmacare Holdings Ltd - Key offerings
Exhibit 110: Aspen Pharmacare Holdings Ltd - Segment focus
12.4 B.Braun SE
Exhibit 111: B.Braun SE - Overview
Exhibit 112: B.Braun SE - Business segments
Exhibit 113: B.Braun SE - Key news
Exhibit 114: B.Braun SE - Key offerings
Exhibit 115: B.Braun SE - Segment focus
12.5 Baxter International Inc.
Exhibit 116: Baxter International Inc. - Overview
Exhibit 117: Baxter International Inc. - Business segments
Exhibit 118: Baxter International Inc. - Key news
Exhibit 119: Baxter International Inc. - Key offerings
Exhibit 120: Baxter International Inc. - Segment focus
12.6 Eisai Co. Ltd.
Exhibit 121: Eisai Co. Ltd. - Overview
Exhibit 122: Eisai Co. Ltd. - Business segments
Exhibit 123: Eisai Co. Ltd. - Key offerings
Exhibit 124: Eisai Co. Ltd. - Segment focus
12.7 Fresenius SE and Co. KGaA
Exhibit 125: Fresenius SE and Co. KGaA - Overview
Exhibit 126: Fresenius SE and Co. KGaA - Business segments
Exhibit 127: Fresenius SE and Co. KGaA - Key news
Exhibit 128: Fresenius SE and Co. KGaA - Key offerings
Exhibit 129: Fresenius SE and Co. KGaA - Segment focus
12.8 Hikma Pharmaceuticals Plc
Exhibit 130: Hikma Pharmaceuticals Plc - Overview
Exhibit 131: Hikma Pharmaceuticals Plc - Business segments
Exhibit 132: Hikma Pharmaceuticals Plc - Key offerings
Exhibit 133: Hikma Pharmaceuticals Plc - Segment focus
12.9 Laboratorios Farmaceuticos ROVI S A
Exhibit 134: Laboratorios Farmaceuticos ROVI S A - Overview
Exhibit 135: Laboratorios Farmaceuticos ROVI S A - Business segments
Exhibit 136: Laboratorios Farmaceuticos ROVI S A - Key offerings
Exhibit 137: Laboratorios Farmaceuticos ROVI S A - Segment focus
12.10 Nanjing Kingfriend Biochemical
Exhibit 138: Nanjing Kingfriend Biochemical - Overview
Exhibit 139: Nanjing Kingfriend Biochemical - Product / Service
Exhibit 140: Nanjing Kingfriend Biochemical - Key offerings
12.11 Nichi Iko Pharmaceutical Co. Ltd.
Exhibit 141: Nichi Iko Pharmaceutical Co. Ltd. - Overview
Exhibit 142: Nichi Iko Pharmaceutical Co. Ltd. - Product / Service
Exhibit 143: Nichi Iko Pharmaceutical Co. Ltd. - Key offerings
12.12 Novartis AG
Exhibit 144: Novartis AG - Overview
Exhibit 145: Novartis AG - Business segments
Exhibit 146: Novartis AG - Key offerings
Exhibit 147: Novartis AG - Segment focus
12.13 Pfizer Inc.
Exhibit 148: Pfizer Inc. - Overview
Exhibit 149: Pfizer Inc. - Product / Service
Exhibit 150: Pfizer Inc. - Key news
Exhibit 151: Pfizer Inc. - Key offerings
12.14 Sanofi SA
Exhibit 152: Sanofi SA - Overview
Exhibit 153: Sanofi SA - Business segments
Exhibit 154: Sanofi SA - Key news
Exhibit 155: Sanofi SA - Key offerings
Exhibit 156: Sanofi SA - Segment focus
12.15 Shenzhen Techdow Pharmaceutical
Exhibit 157: Shenzhen Techdow Pharmaceutical - Overview
Exhibit 158: Shenzhen Techdow Pharmaceutical - Product / Service
Exhibit 159: Shenzhen Techdow Pharmaceutical - Key offerings
12.16 Teva Pharmaceutical Industries Ltd.
Exhibit 160: Teva Pharmaceutical Industries Ltd. - Overview
Exhibit 161: Teva Pharmaceutical Industries Ltd. - Business segments
Exhibit 162: Teva Pharmaceutical Industries Ltd. - Key news
Exhibit 163: Teva Pharmaceutical Industries Ltd. - Key offerings
Exhibit 164: Teva Pharmaceutical Industries Ltd. - Segment focus
12.17 Viatris Inc.
Exhibit 165: Viatris Inc. - Overview
Exhibit 166: Viatris Inc. - Business segments
Exhibit 167: Viatris Inc. - Key news
Exhibit 168: Viatris Inc. - Key offerings
Exhibit 169: Viatris Inc. - Segment focus

13 Appendix

13.1 Scope of the report
13.2 Inclusions and exclusions checklist
Exhibit 170: Inclusions checklist
Exhibit 171: Exclusions checklist
13.3 Currency conversion rates for US$
Exhibit 172: Currency conversion rates for US$
13.4 Research methodology
Exhibit 173: Research methodology
Exhibit 174: Validation techniques employed for market sizing
Exhibit 175: Information sources
13.5 List of abbreviations
Exhibit 176: List of abbreviations